Insider · CIK 0001438421

Webster Stephen W

Reports to the SEC for 12 companies · BELTSVILLE, MD

sec.gov

Transactions

Companies

Filings

CIK

0001438421

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-18	NXTCNextCure, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+2,340 sh	—	—	2,340
2026-06-16	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+25.3K sh	—	—	25,319
2026-06-08	ELOXEloxx Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+13.6K sh	—	—	13,587
2025-06-20	NXTCNextCure, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18.7K sh	—	—	18,700
2025-06-12	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+38.5K sh	—	—	38,513
2025-04-04	Gritstone bio, Inc.J Other	Director	JOther	−25K sh	—	—	0
2025-04-04	Gritstone bio, Inc.Stock Option (Right to Buy)J Other	Director	JOther	−104K sh	—	—	0
2025-04-04	Gritstone bio, Inc.Stock Option (Right to Buy)J Other	Director	JOther	−7,379 sh	—	—	0
2024-06-26	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15.8K sh	—	—	15,806
2024-06-20	NXTCNextCure, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18.7K sh	—	—	18,700
2024-06-17	Gritstone bio, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+7,379 sh	—	—	7,379
2024-04-26	Gritstone bio, Inc.Stock Option (Right to Buy)A Award	Director	AAward	+104K sh	—	—	103,600
2023-06-22	NXTCNextCure, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+14.3K sh	—	—	14,250
2023-06-08	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+18.5K sh	—	—	18,450
2023-06-01	TCR2 THERAPEUTICS INC.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−16.8K sh	—	—	0
2023-06-01	TCR2 THERAPEUTICS INC.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−12.1K sh	—	—	0
2023-06-01	TCR2 THERAPEUTICS INC.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−12.1K sh	—	—	0
2023-06-01	TCR2 THERAPEUTICS INC.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10.5K sh	—	—	0
2022-12-15	TCR2 THERAPEUTICS INC.Stock Option (Right to Buy)A Award	Director	AAward	+16.8K sh	—	—	16,800
2022-08-02	Nabriva Therapeutics plcS Sale	Director	SSale	−7,826 sh	$0.19	−$1,486.94	11,447
2022-06-23	NXTCNextCure, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+14.3K sh	—	—	14,250
2022-06-22	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+16.5K sh	—	—	16,475
2021-12-09	TCR2 THERAPEUTICS INC.Stock Option (Right to Buy)A Award	Director	AAward	+12.1K sh	—	—	12,100
2021-09-16	CGEMCullinan Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+7,800 sh	—	—	7,800
2021-08-02	Nabriva Therapeutics plcS Sale	Director	SSale	−777 sh	$1.20	−$932.4	19,273
2021-07-28	Nabriva Therapeutics plcA Award	Director	AAward	+17.5K sh	—	—	20,050
2021-07-28	Nabriva Therapeutics plcShare OptionsA Award	Director	AAward	+35K sh	—	—	35,000
2021-06-24	NXTCNextCure, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+14.3K sh	—	—	14,250
2020-12-10	TCR2 THERAPEUTICS INC.Stock Option (Right to Buy)A Award	Director	AAward	+12.1K sh	—	—	12,100
2020-07-29	Nabriva Therapeutics plcA Award	Director	AAward	+17.5K sh	—	—	25,500
2020-07-29	Nabriva Therapeutics plcStock OptionsA Award	Director	AAward	+35K sh	—	—	35,000
2020-06-11	NXTCNextCure, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+14.3K sh	—	—	14,250
2020-04-30	TCR2 THERAPEUTICS INC.Stock Option (Right to Buy)A Award	Director	AAward	+10.5K sh	—	—	10,482
2020-01-02	VKTXViking Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22K sh	—	—	22,000
2019-12-17	Spark Therapeutics, Inc.U Disposition from Tender	CHIEF FINANCIAL OFFICER	UDisposition from Tender	−6,102 sh	$114.50	−$699K	0
2019-12-17	Spark Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	CHIEF FINANCIAL OFFICER	DDisposition to Issuer	−35K sh	—	—	0
2019-12-17	Spark Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	CHIEF FINANCIAL OFFICER	DDisposition to Issuer	−28K sh	—	—	0
2019-12-17	Spark Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	CHIEF FINANCIAL OFFICER	DDisposition to Issuer	−25K sh	—	—	0
2019-12-17	Spark Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	CHIEF FINANCIAL OFFICER	DDisposition to Issuer	−55K sh	—	—	0
2019-12-17	Spark Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	CHIEF FINANCIAL OFFICER	DDisposition to Issuer	−60K sh	—	—	0
2019-12-17	Spark Therapeutics, Inc.Stock Option (Right to Buy)D Disposition to Issuer	CHIEF FINANCIAL OFFICER	DDisposition to Issuer	−106K sh	—	—	0
2019-12-17	Spark Therapeutics, Inc.Restricted Stock UnitsD Disposition to Issuer	CHIEF FINANCIAL OFFICER	DDisposition to Issuer	−19.5K sh	—	—	0
2019-07-31	Nabriva Therapeutics plcStock OptionA Award	Director	AAward	+35K sh	—	—	35,000
2019-06-13	NXTCNextCure, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22K sh	—	—	22,000
2019-01-18	Spark Therapeutics, Inc.M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	+1,750 sh	—	—	5,365
2019-01-18	Spark Therapeutics, Inc.F Tax Payment	CHIEF FINANCIAL OFFICER	FTax Payment	−634 sh	$45.08	−$28.6K	4,731
2019-01-18	Spark Therapeutics, Inc.M Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	+2,000 sh	—	—	6,731
2019-01-18	Spark Therapeutics, Inc.F Tax Payment	CHIEF FINANCIAL OFFICER	FTax Payment	−629 sh	$45.08	−$28.4K	6,102
2019-01-18	Spark Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	−1,750 sh	—	—	3,500
2019-01-18	Spark Therapeutics, Inc.Restricted Stock UnitsM Exercise/Conversion	CHIEF FINANCIAL OFFICER	MExercise/Conversion	−2,000 sh	—	—	6,000

Recent filings

Accepted (ET)
Jun 224
Webster Stephen W0000905148-26-003043
SEC(opens sec.gov)
Jun 184
Webster Stephen W0001193125-26-276057
SEC(opens sec.gov)
Jun 104
Webster Stephen W0001193125-26-266279
SEC(opens sec.gov)
Jun 244
Webster Stephen W0000905148-25-002242
SEC(opens sec.gov)
Jun 164
Webster Stephen W0000950170-25-086726
SEC(opens sec.gov)
Apr 84
Webster Stephen W0001415889-25-010435
SEC(opens sec.gov)
Jun 274
Webster Stephen W0000950170-24-078678
SEC(opens sec.gov)
Jun 214
Webster Stephen W0000905148-24-001769
SEC(opens sec.gov)
Jun 204
Webster Stephen W0001415889-24-017705
SEC(opens sec.gov)
Apr 304
Webster Stephen W0001415889-24-011805
SEC(opens sec.gov)
Jun 234
Webster Stephen W0001140361-23-031188
SEC(opens sec.gov)
Jun 124
Webster Stephen W0000950170-23-027538
SEC(opens sec.gov)
Jun 14
Webster Stephen W0001104659-23-067057
SEC(opens sec.gov)
Dec 194
Webster Stephen W0000899243-22-039006
SEC(opens sec.gov)
Aug 44
Webster Stephen W0001104659-22-086279
SEC(opens sec.gov)

Companies

Address

C/O NEXTCURE, INC. 9000 VIRGINIA MANOR ROAD, SUITE 200

BELTSVILLE, MD, 20705